Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:6a1d08cd2b86d7d9af7c09bd3dcb9030]

Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:6a1d08cd2b86d7d9af7c09bd3dcb9030]

Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:6a1d08cd2b86d7d9af7c09bd3dcb9030
Safety and Immune Response to Recombinant Live-Attenuated Influenza H2N2 Virus Vaccine [clinicaltrials:NCT00722774]
clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Frequency of vaccine-related reactogenicity events and other adverse events Throughout study [clinicaltrials_resource:6a1d08cd2b86d7d9af7c09bd3dcb9030]

Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Primary outcome [clinicaltrials_vocabulary:primary-outcome]
http://bio2rdf.org/clinicaltrials_resource:6a1d08cd2b86d7d9af7c09bd3dcb9030
Bio2RDF identifier
6a1d08cd2b86d7d9af7c09bd3dcb9030
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:6a1d08cd2b86d7d9af7c09bd3dcb9030
measure [clinicaltrials_vocabulary:measure]
Frequency of vaccine-related reactogenicity events and other adverse events
time frame [clinicaltrials_vocabulary:time-frame]
description
Participants will receive 2 doses of vaccine 4 to 8 weeks (28-62 days) apart
identifier
clinicaltrials_resource:6a1d08cd2b86d7d9af7c09bd3dcb9030
title
Frequency of vaccine-related r ...... dverse events Throughout study
@en
inDataset
type
label
Frequency of vaccine-related r ...... d08cd2b86d7d9af7c09bd3dcb9030]
@en